Figure S3 from First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas

Figure S3 from First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas

<p>Supplemental figure correlating biological variance ratio (BVR) to contrast-to-variance ratio (CVR).</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Kimberley S. Samkoe (20877828) (author)
مؤلفون آخرون:	Hira Shahzad Sardar (21233329) (author), Jason R. Gunn (21233332) (author), Jonathan Thomas Elliott (21233335) (author), Sally Mansur (21233338) (author), Joachim Feldwisch (21233341) (author), Brian W. Pogue (17534777) (author), Konstantinos Linos (21233344) (author), Keith D. Paulsen (17534780) (author), Eric R. Henderson (21233347) (author)
منشور في:	2025
الموضوعات:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Methods and Technology Biological Agents & Therapies Antireceptors Clinical Imaging Clinical Trial Results Engineering Imaging Imaging probes Sarcomas Soft-tissue sarcoma
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Figure S1 from First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas
حسب: Kimberley S. Samkoe (20877828)
منشور في: (2025)

Figure S2 from First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas
حسب: Kimberley S. Samkoe (20877828)
منشور في: (2025)

Schematic 1 from First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas
حسب: Kimberley S. Samkoe (20877828)
منشور في: (2025)

Figure 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Figure 2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Figure 3 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Figure 4 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Figure 5 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Table 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Supplementary Table S1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Supplementary Table S2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Supplementary Table S3 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
حسب: Valeriya Pankova (19275494)
منشور في: (2024)

Figure 2 from Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly
حسب: Cecilia Sgadari (15086851)
منشور في: (2025)

Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
حسب: Takafumi Koyama (15035714)
منشور في: (2025)

Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
حسب: Takafumi Koyama (15035714)
منشور في: (2025)

Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
حسب: Takafumi Koyama (15035714)
منشور في: (2025)

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
حسب: Takafumi Koyama (15035714)
منشور في: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
حسب: Nam Q. Bui (14958210)
منشور في: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Figure S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Figure S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Table S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Table S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
حسب: Roberto Carmagnani Pestana (15294422)
منشور في: (2025)

Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
حسب: Johanna Falkenhorst (15039017)
منشور في: (2025)

Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
حسب: Johanna Falkenhorst (15039017)
منشور في: (2025)

Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
حسب: Johanna Falkenhorst (15039017)
منشور في: (2025)

Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
حسب: Johanna Falkenhorst (15039017)
منشور في: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
حسب: Srivandana Akshintala (16610490)
منشور في: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
حسب: Srivandana Akshintala (16610490)
منشور في: (2025)

Figure 1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Figure 2 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Figure 3 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Figure 4 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Table 1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Table 2 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
حسب: William D. Tap (15017801)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ltrfiunc1ac8d55ia6tav1eu9b